[go: up one dir, main page]

SMT201900609T1 - Metodo di dosaggio metronomico con profarmaci di camptotecina (ad esempio pegirinotecano) - Google Patents

Metodo di dosaggio metronomico con profarmaci di camptotecina (ad esempio pegirinotecano)

Info

Publication number
SMT201900609T1
SMT201900609T1 SM20190609T SMT201900609T SMT201900609T1 SM T201900609 T1 SMT201900609 T1 SM T201900609T1 SM 20190609 T SM20190609 T SM 20190609T SM T201900609 T SMT201900609 T SM T201900609T SM T201900609 T1 SMT201900609 T1 SM T201900609T1
Authority
SM
San Marino
Prior art keywords
irinotecan
peg
metronomic dosing
camptothecin prodrugs
camptothecin
Prior art date
Application number
SM20190609T
Other languages
English (en)
Inventor
Michael A Eldon
Shibani S Harite
Tamra L Barker
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of SMT201900609T1 publication Critical patent/SMT201900609T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SM20190609T 2008-09-23 2009-09-23 Metodo di dosaggio metronomico con profarmaci di camptotecina (ad esempio pegirinotecano) SMT201900609T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US10693108P 2008-10-20 2008-10-20
US17343309P 2009-04-28 2009-04-28
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
EP09789364.8A EP2349346B1 (en) 2008-09-23 2009-09-23 Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)

Publications (1)

Publication Number Publication Date
SMT201900609T1 true SMT201900609T1 (it) 2020-01-14

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190609T SMT201900609T1 (it) 2008-09-23 2009-09-23 Metodo di dosaggio metronomico con profarmaci di camptotecina (ad esempio pegirinotecano)

Country Status (21)

Country Link
US (3) US8906353B2 (it)
EP (1) EP2349346B1 (it)
JP (3) JP2012503602A (it)
KR (1) KR20110063457A (it)
CN (1) CN102164617A (it)
AU (1) AU2009297091B2 (it)
CA (1) CA2736939C (it)
CY (1) CY1122208T1 (it)
DK (1) DK2349346T3 (it)
ES (1) ES2744975T3 (it)
HR (1) HRP20192120T1 (it)
HU (1) HUE047352T2 (it)
IL (1) IL211888A (it)
LT (1) LT2349346T (it)
MX (1) MX2011003063A (it)
PL (1) PL2349346T3 (it)
PT (1) PT2349346T (it)
RS (1) RS59607B1 (it)
SI (1) SI2349346T1 (it)
SM (1) SMT201900609T1 (it)
WO (1) WO2010036335A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009297091B2 (en) 2008-09-23 2015-03-05 Nektar Therapeutics Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
CN109608436B (zh) * 2011-04-08 2022-10-11 斯法尔制药私人有限公司 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法
WO2014085571A1 (en) * 2012-11-28 2014-06-05 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
US10835548B2 (en) 2016-06-02 2020-11-17 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
EP3852793A4 (en) 2018-09-17 2022-07-13 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
WO2022182655A2 (en) * 2021-02-23 2022-09-01 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
AU2001280679A1 (en) 2000-07-21 2002-02-05 Prad Research And Development N.V. Nuclear magnetic resonance methods for extracting information about a fluid in arock
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
WO2003037384A2 (en) 2001-10-29 2003-05-08 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
DE60219677T2 (de) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
AU2003251405A1 (en) 2002-06-06 2003-12-22 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
PT1675622T (pt) * 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
WO2007098091A2 (en) * 2006-02-17 2007-08-30 Novacea, Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
JP2010518120A (ja) * 2007-02-09 2010-05-27 エンゾン ファーマスーティカルズ インコーポレイテッド 7−エチル−10−ヒドロキシカンプトテシンのマルチアームポリマー複合体を用いた抵抗性または難治性の癌の治療方法
CN101199857B (zh) * 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
AU2009297091B2 (en) 2008-09-23 2015-03-05 Nektar Therapeutics Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Also Published As

Publication number Publication date
EP2349346A1 (en) 2011-08-03
AU2009297091B2 (en) 2015-03-05
MX2011003063A (es) 2011-04-21
JP2015034180A (ja) 2015-02-19
CY1122208T1 (el) 2020-11-25
PL2349346T3 (pl) 2020-03-31
HUE047352T2 (hu) 2020-04-28
US20110269789A1 (en) 2011-11-03
JP2016216510A (ja) 2016-12-22
ES2744975T3 (es) 2020-02-27
LT2349346T (lt) 2019-09-25
US9801873B2 (en) 2017-10-31
PT2349346T (pt) 2019-10-24
US20150087668A1 (en) 2015-03-26
US8906353B2 (en) 2014-12-09
CA2736939C (en) 2021-09-14
IL211888A (en) 2015-08-31
SI2349346T1 (sl) 2019-12-31
RS59607B1 (sr) 2020-01-31
IL211888A0 (en) 2011-06-30
US10525051B2 (en) 2020-01-07
JP6076317B2 (ja) 2017-02-08
DK2349346T3 (da) 2019-10-07
US20180028525A1 (en) 2018-02-01
KR20110063457A (ko) 2011-06-10
HRP20192120T1 (hr) 2020-02-21
CA2736939A1 (en) 2010-04-01
JP2012503602A (ja) 2012-02-09
AU2009297091A1 (en) 2010-04-01
EP2349346B1 (en) 2019-08-28
WO2010036335A1 (en) 2010-04-01
CN102164617A (zh) 2011-08-24

Similar Documents

Publication Publication Date Title
RS59607B1 (sr) Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
AP3408A (en) Tobacco curing method
GB0822893D0 (en) Advanced speed profiles - Further updates
IL209382A0 (en) Water-soluble acetaminophen analogs
HUE036937T2 (hu) Neodímiummal katalizált polibutadién
GB2462829B (en) Measurement method
GB0803107D0 (en) Method
EP2336393A4 (en) GALVANOPLASTY PROCESS
ZA201009263B (en) Plant regulatory sequences
GB0807409D0 (en) Method
GB0804981D0 (en) Method
GB0807410D0 (en) Method
GB0804690D0 (en) Method
EP2309852A4 (en) NOVEL PROCEDURE
EP2239093A4 (en) PRODUCTION INSTALLATION
GB0809404D0 (en) Method
EP2321435A4 (en) WIEDERAUFKOHLUNGSVERFAHREN
GB0805862D0 (en) Method
AU326445S (en) Meter
GB0908678D0 (en) Metering apparatus
GB0806186D0 (en) Method
GB0804242D0 (en) Clopidogrel solution
GB0812957D0 (en) Quwb-it (game)
GB0817782D0 (en) Game method
GB0819828D0 (en) Measurement method